Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Results of portosystemic shunts during extended pancreatic resections.

Oehme F, Distler M, Müssle B, Kahlert C, Weitz J, Welsch T.

Langenbecks Arch Surg. 2019 Aug 24. doi: 10.1007/s00423-019-01816-8. [Epub ahead of print]

PMID:
31446472
2.

CCR5 status and metastatic progression in colorectal cancer.

Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N.

Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019.

3.

c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.

Lux A, Kahlert C, Grützmann R, Pilarsky C.

Int J Mol Sci. 2019 Jul 5;20(13). pii: E3305. doi: 10.3390/ijms20133305.

4.

Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer.

Oehme F, Krahl S, Gyorffy B, Muessle B, Rao V, Greif H, Ziegler N, Lin K, Thepkaysone ML, Polster H, Tonn T, Schneider M, Weitz J, Baenke F, Kahlert C.

RNA Biol. 2019 Oct;16(10):1339-1345. doi: 10.1080/15476286.2019.1637697. Epub 2019 Jul 7.

PMID:
31251124
5.

Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes.

Rahbari M, Pecqueux M, Aust D, Stephan H, Tiebel O, Chatzigeorgiou A, Tonn T, Baenke F, Rao V, Ziegler N, Greif H, Lin K, Weitz J, Rahbari NN, Kahlert C.

J Clin Med. 2019 May 16;8(5). pii: E696. doi: 10.3390/jcm8050696.

6.

Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?

Kahlert C.

Cancer Res. 2019 May 15;79(10):2462-2465. doi: 10.1158/0008-5472.CAN-19-0019. Epub 2019 May 1.

PMID:
31043377
7.

[Outpatient Drain Management in Patients with Clinically Relevant Postoperative Pancreatic Fistula (CR-POPF) - Current Status in Germany].

Hempel S, Püttmann P, Kahlert C, Seifert L, Mees ST, Welsch T, Weitz J, Distler M.

Zentralbl Chir. 2018 Jun;143(3):270-277. doi: 10.1055/a-0608-4432. Epub 2018 Jun 22. German.

PMID:
29933481
8.

Prognostic Impact of Bacterobilia on Morbidity and Postoperative Management After Pancreatoduodenectomy: A Systematic Review and Meta-analysis.

Müssle B, Hempel S, Kahlert C, Distler M, Weitz J, Welsch T.

World J Surg. 2018 Sep;42(9):2951-2962. doi: 10.1007/s00268-018-4546-5. Review.

PMID:
29464345
9.

Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection.

Yang C, Bork U, Schölch S, Kulu Y, Kaderali L, Bolstorff UL, Kahlert C, Weitz J, Rahbari NN, Reissfelder C.

Oncotarget. 2017 Aug 17;8(42):72315-72323. doi: 10.18632/oncotarget.20315. eCollection 2017 Sep 22.

10.

Outpatient Drainmanagement of patients with clinically relevant Postoperative Pancreatic Fistula (POPF).

Hempel S, Wolk S, Kahlert C, Kersting S, Weitz J, Welsch T, Distler M.

Langenbecks Arch Surg. 2017 Aug;402(5):821-829. doi: 10.1007/s00423-017-1595-4. Epub 2017 Jun 8.

PMID:
28597036
11.

Prognostic value of circulating endothelial cells in metastatic colorectal cancer.

Rahbari NN, Schölch S, Bork U, Kahlert C, Schneider M, Rahbari M, Büchler MW, Weitz J, Reissfelder C.

Oncotarget. 2017 Jun 6;8(23):37491-37501. doi: 10.18632/oncotarget.16397.

12.

Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.

Berthel A, Zoernig I, Valous NA, Kahlert C, Klupp F, Ulrich A, Weitz J, Jaeger D, Halama N.

Oncoimmunology. 2017 Feb 23;6(3):e1286436. doi: 10.1080/2162402X.2017.1286436. eCollection 2017.

13.

Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer.

Lerbs T, Bisht S, Schölch S, Pecqueux M, Kristiansen G, Schneider M, Hofmann BT, Welsch T, Reissfelder C, Rahbari NN, Fritzmann J, Brossart P, Weitz J, Feldmann G, Kahlert C.

BMC Cancer. 2017 Apr 7;17(1):249. doi: 10.1186/s12885-017-3225-5.

14.

A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival.

Pecqueux M, Liebetrau I, Werft W, Dienemann H, Muley T, Pfannschmidt J, Müssle B, Rahbari N, Schölch S, Büchler MW, Weitz J, Reissfelder C, Kahlert C.

Int J Mol Sci. 2016 Oct 21;17(10). pii: E1755.

15.

LDB1 overexpression is a negative prognostic factor in colorectal cancer.

García SA, Swiersy A, Radhakrishnan P, Branchi V, Kanth Nanduri L, Győrffy B, Betzler AM, Bork U, Kahlert C, Reißfelder C, Rahbari NN, Weitz J, Schölch S.

Oncotarget. 2016 Dec 20;7(51):84258-84270. doi: 10.18632/oncotarget.12481.

16.

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.

Schmitz R, Valls AF, Yerbes R, von Richter S, Kahlert C, Loges S, Weitz J, Schneider M, Ruiz de Almodovar C, Ulrich A, Schmidt T.

Oncotarget. 2016 Aug 30;7(35):56355-56370. doi: 10.18632/oncotarget.10889.

17.

Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients.

Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, Ulrich A.

BMC Cancer. 2016 Jul 18;16:494. doi: 10.1186/s12885-016-2515-7.

18.

Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer.

Rahbari M, Rahbari N, Reissfelder C, Weitz J, Kahlert C.

Langenbecks Arch Surg. 2016 Dec;401(8):1097-1110. Epub 2016 Jun 24. Review.

PMID:
27342853
19.

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D.

Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

20.

Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.

Schölch S, García SA, Iwata N, Niemietz T, Betzler AM, Nanduri LK, Bork U, Kahlert C, Thepkaysone ML, Swiersy A, Büchler MW, Reissfelder C, Weitz J, Rahbari NN.

Oncotarget. 2016 May 10;7(19):27232-42. doi: 10.18632/oncotarget.8373.

Supplemental Content

Loading ...
Support Center